Address

Abingworth Bioventures III LP
38 Jermyn Street
London
SW1Y 6DN
United Kingdom

Open Map


VCID: 24408
    Profile

    Corporate information

    Official name
    Abingworth Bioventures III LP

    Registration country
    Investment activity status
    Not investing

    Company type

    Venture capital fund

    Fund terms

    Vintage
    2001
    Fund type

    Funding rounds

    Fund Closing USD 225,000,000


    USD 225,000,000 (31 Dec 2001)

    Selected investments

    Country Date Notes
    Xenogen Corp
    United States 31 Dec 2003 N/A
    Active
    Alnylam Pharmaceuticals Inc
    United States 31 Dec 2002 N/A
    Active
    Labcyte Inc
    United States 31 Dec 2002 N/A
    Active
    Biolmage
    Denmark 31 Dec 2002 N/A
    Active
    Galapagos NV
    Belgium 31 Dec 2002 N/A
    Active
    XCounter
    Sweden 31 Dec 2002 Other
    Active
    Hydra Biosciences Inc
    United States 31 Dec 2002 N/A
    Active
    ParAllele BioScience Inc
    United States 31 Dec 2001 N/A
    Active
    Chroma Therapeutics Ltd
    Focused on harnessing the power of chromatin biology and novel drug accumulation approaches to discover and develop a new generation of targeted cance
    United Kingdom 31 Dec 2001 N/A
    Active
    Guava Technologies Inc
    A biotechnology company providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing.
    United States 31 Dec 2001 N/A
    Active
    Akubio Ltd
    Provider of acoustic detection systems for real time analysis of biomolecular behavior
    United States 31 Dec 2001 N/A
    Active
    Inpharmatica Ltd
    United Kingdom 31 Dec 2001 N/A
    Active
    Astex Pharmaceuticals Inc
    Drug discovery, development and commercialization.
    United States 31 Dec 1999 N/A
    Active
    Lorantis
    United States 31 Dec 1998 N/A
    Active
    Solexa Ltd
    United Kingdom 31 Dec 1998 N/A
    Active

    DISCLAIMER: This chart is based on a limited amount of data and may change once additional information has been added. We are working hard to ensure the completeness of the data. If you want to assist us in our work, please contact us using this form.